Capitalmind
Capitalmind
Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial

15 ArticlesLupin

2 / 2

Exclusive: Lupin Pharmaceuticals slapped form 483 for Mandideep facility

Welcome to the third and final part of the 3 part exclusive unwrapping of the observations reported from the US FDA’s inspection of Lupin Pharmaceutical’s ...

Apr 07, 2016

04-Lupin-fda-3-facilities-Mandideep.png

Exclusive: Lupin Pharmaceuticals slapped form 483 for Goa facility

Welcome to the second of the 3 part exclusive unwrapping of the observations reported from the US FDA’s inspection of Lupin Pharmaceutical’s facilities. If ...

Apr 07, 2016

03-Lupin-fda-3-facilities-Goa.png

Exclusive: Lupin Pharmaceuticals slapped form 483 for Aurangabad facility

Welcome to the first of the 3 part exclusive unwrapping of the observations reported from the US FDA’s inspection of Lupin Pharmaceutical’s facilities. If ...

Apr 07, 2016

02-Lupin-fda-3-facilities-Aurangabad.png

Exclusive: Lupin Pharmaceuticals slapped form 483 for 3 facilities

Today we at Capital Mind bring you some exclusive articles. This follows our earlier post on Lupin’s Mandideep facility FDA inspection which was brought to ...

Apr 07, 2016

01-Lupin-fda-3-facilities.png

Lupin’s tussle with the FDA and Investors – a lesson for the Pharma Industry

Lupin was and is all over the news. Why? Yesterday IIFL published an article in relation to the FDA’s inspection of Lupin’s Mandideep facility based on a ...

Mar 30, 2016

Lupin-Share-Price.png

Join Capitalmind Premium

Starts at ₹1,999/mo

Get access to our equity, fixed income, macro and personal finance research, model equity and fixed-income portfolios, exclusive apps, tutorials, and member community.